Tenaya Therapeutics Reports Interim Phase 1b/2 TN-401 Data Showing Up To 84% Reduction In Arrhythmia Burden In PKP2-Associated ARVC Patients

Benzinga Newsdesk www.benzinga.com Positive 88.6%